Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial.
Anticancer Res
; 40(4): 2053-2057, 2020 Apr.
Article
en En
| MEDLINE
| ID: mdl-32234896
ABSTRACT
BACKGROUND:
The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer. PATIENTS ANDMETHODS:
We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015.RESULTS:
The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Seven (28%) patients received neoadjuvant androgen-deprivation therapy. The median follow-up time was 53 months. Grade 2 acute and late genitourinary toxicities were observed in five (20%) and two (8%) patients and there were no Grade 2 gastrointestinal toxicities. There were no Grade 3 or higher acute or late toxicities at 2 years follow-up. The biochemical relapse-free survival rate at 2 years was 100%.CONCLUSION:
SBRT of 35 Gy per five fractions is a promising treatment method in the short term for prostate cancer.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Radiocirugia
/
Tracto Gastrointestinal
/
Andrógenos
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Anticancer Res
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón